In patients with immunoglobulin A nephropathy (IgAN), higher levels of proteinuria and lower baseline estimated glomerular filtration rate (eGFR) are strongly associated with adverse kidney outcomes — ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Pierre Fabre Labs expands R&D portfolio; announces acquisition of the worldwide rights for PFL-721 & PFL-241: Castres, France Wednesday, June 18, 2025, 11:00 Hrs [IST] Pierre Fabr ...

Mineralys reports Phase 2 trial success for lorundrostat, showing BP and kidney improvements in CKD patients with favorable ...

New Team Science Award is $1.5 million Over Three Years NEW YORK, June 17, 2025 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) announces today ...

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

On April 29, 2025, Vivoryon disclosed preclinical data from a series of experiments in a chronic kidney disease animal model, analyzing different treatment regimens of varoglutamstat in combination ...

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

SGLT2 inhibitors have been shown to reduce risk of acute kidney injury, but whether kidney effects are modified by risk of acute dips in eGFR is unknown.

PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical ...